Otsaw Launches World’s First UV-C LED Disinfection Autonomous Robot

First Deployment at Wisma Atria, Singapore Starting from 15 July 2020

June 16, 2020

Otsaw Digital Pte. Ltd. (“Otsaw“) announced that it has launched the world’s first UV-C LED Disinfection Autonomous Robot, named “O-RX”. Underscoring Otsaw’s strengths in the design and development of autonomous robotics and the integration of innovative UV-C LED technology, Otsaw has filed the relevant patents for this new innovation.

Otsaw notes from conceptualization, design, materials procurement, prototype testing to certification, the development of the O-RX was successfully completed in a short 8 weeks.

As a testament to its high safety standards and product quality, the O-RX has undergone the relevant safety and testing under various conditions and it has been certified by internationally-accredited TUV SUD.

Eliminating the use of mercury lamps that emits harmful UV-A and UV-B radiations, the O-RX utilises the UV-C LED technology that emits only UV-C light, which is extremely effective when it comes to killing microbes, including harmful bacteria and coronaviruses such as COVID-19. Hence, the UV-C LED technology is much safer and non-cancerous to human skin.

Integrated with the innovative UV-C LED technology, the O-RX has a disinfection rate of more than 99.999% with a range of 2.5 meters and the UV-C LED technology is also more energy-efficient than conventional mercury lamps by 70%.

Capable to be deployed for 5 hours on one full charge, the O-RX is also equipped with a 360-degree camera and lidar sensors with self-driving, collision avoidance and artificial intelligence technologies. The O-RX can be controlled and managed remotely via a fleet management control platform that is developed by Otsaw.

To help remove heat generated by the LED, the robot uses a thermal management solution developed by researchers at the Agency for Science, Technology and Research’s (A*STAR) Singapore Institute of Manufacturing Technology (SIMTech).

Otsaw will be collaborating with YTL Starhill Global REIT Management Limited, the manager of Starhill Global REIT, and will be running a trial of the O-RX at Wisma Atria commencing from 15 July 2020.

Otsaw’s founder and CEO, Mr Ling Ting Ming, commented, “Disinfection is a key part of protecting the health and safety of communities and more than ever, we need to accelerate the rate of automating disinfection as COVID-19 outbreak increased the demand and frequencies of disinfection but at the same time, manpower resources have been curtailed.

“O-RX combines innovative LED technology and robotics to allow the disinfecting process to be fully autonomous, mobile and much safer, thereby achieving a higher disinfection efficiency as compared to conventional methods and reduce the dependence of human resources.”

 

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.